R. Axelrod

发表

Human papillomavirus and survival of patients with oropharyngeal cancer.

K. Ang, R. Weber, C. Chung, 2010, The New England journal of medicine.

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Sue S Yom, Wade L Thorstad, Adam S Garden, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome.

K. Ang, R. Weber, Q. Zhang, 2010 .

Neutrophil to lymphocyte ratio associated with prognosis of lung cancer

M. Werner-wasik, V. Bar-ad, R. Myers, 2017, Clinical and Translational Oncology.

Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy.

W. Curran, W. Hauck, M. Werner-wasik, 2001, Clinical lung cancer.

A Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Efficacy and Toxicity

R. Weber, T. Pajak, R. Wheeler, 2010 .

Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect

B. Leiby, A. Argiris, A. Flanders, 2020, Frontiers in Oncology.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

V. Devanarayan, K. Pittman, T. Owonikoko, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.

W. Curran, A. Dicker, G. Kubicek, 2008, International journal of radiation oncology, biology, physics.

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck

A. Argiris, B. Burtness, R. Axelrod, 2011, Cancer.

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

R. Govindan, D. Carbone, P. Fidias, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).

A. Garden, K. Ang, R. Weber, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lactate metabolism in patients with metastatic colorectal cancer.

P. Paul, G. Reichard, R. Axelrod, 1979, Cancer research.

Uncommon Tumors of the Oral Cavity and Adjacent Structures

V. Bar-ad, R. Axelrod, D. Cognetti, 2012 .

Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy.

W. Curran, W. Hauck, R. Axelrod, 2002, Seminars in radiation oncology.

Reply to D. Adkins et al.

A. Garden, Q. Zhang, S. Yom, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neck Dissection Followed by Chemoradiotherapy for Stage IV (N+) Oropharynx Cancer

P. Anné, R. Axelrod, W. Keane, 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

A Phase III Trial to Compare Standard Versus Accelerated Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Compliance and Toxicity

R. Weber, T. Pajak, D. Rosenthal, 2007 .

Clinical results and immunologic effects of a mixed bacterial vaccine in cancer patients

R. Axelrod, M. Goonewardene, D. Murasko, 1993, Medical oncology and tumor pharmacotherapy.

Effect of the mixed bacterial vaccine on the immune response of patients with non‐small cell lung cancer and refractory malignancies

R. Axelrod, D. Murasko, Bonnie Bushnell, 1988, Cancer.

E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer

T. Owonikoko, S. Ramalingam, J. Schiller, 2013, Cancer Chemotherapy and Pharmacology.

Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.

Christopher U. Jones, A. Garden, P. Harari, 2016, International journal of radiation oncology, biology, physics.

An economic model to value companion diagnostics in non-small-cell lung cancer.

Robert D. Lieberthal, N. Goldfarb, R. Axelrod, 2013, Personalized medicine.

Primary osteosarcoma of the kidney

R. Axelrod, H. Naidech, J. Myers, 1978, Cancer.

Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

R. Komaki, B. Movsas, Colum J Smith, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial

Anurag K. Singh, J. Weidhaas, C. Chung, 2017, JAMA oncology.

Sarcoidosis mimicking metastatic bone disease in head and neck cancer.

P. McCue, R. Axelrod, M. Rosen, 2013, Seminars in oncology.

Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments.

Hushan Yang, V. Bar-ad, J. Palmer, 2014, Seminars in oncology.

Endovascular management of carotid blowout.

S. Tjoumakaris, R. Rosenwasser, P. Jabbour, 2012, World neurosurgery.

Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.

A. Dowlati, R. Lilenbaum, R. Axelrod, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Window-of-opportunity trial of nivolumab with or without the IDO inhibitor BMS-986205 in patients with resectable squamous cell carcinoma of the head and neck (SCCHN).

B. Leiby, A. Argiris, U. Rodeck, 2020 .

Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer.

B. Leiby, A. Argiris, V. Bar-ad, 2020 .

Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab

P. Fortina, Nicholas G Zaorsky, A. Dicker, 2013, Cancer biology & therapy.

The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.

J. Bradley, R. Komaki, Y. Lawrence, 2013, Lung cancer.

Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA – N 2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy †

Ronald, Ramalingam, Igor, 2015 .

Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.

B. Leiby, A. Argiris, R. Zinner, 2020 .

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer

Ashley L. Buchanan, J. Kolesar, A. Argiris, 2009, Cancer.

Weekly docetaxel (D) and irinotecan (I) in patients (pts) with recurrent or metastatic head and neck cancer (HNC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG)

A. Argiris, M. Goldwasser, R. Axelrod, 2005 .

Modeling the overall survival of patients with advanced‐stage non‐small cell lung cancer using data of routine laboratory tests

Hushan Yang, T. Hyslop, Bingshan Li, 2015, International journal of cancer.

Abstract A58: Racial disparities in head and neck cancers in an urban hospital

V. Bar-ad, R. Axelrod, C. Zeigler-Johnson, 2018, Epidemiology, Lifestyle, and Genetics.

Introduction: women and lung cancer.

R. Axelrod, 2009, Seminars in oncology.

632 POSTER Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301

J. Manola, A. Argiris, B. Burtness, 2006 .

Safety of nivolumab and ipilimumab in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

A. Argiris, U. Rodeck, R. Zinner, 2019, Journal of Clinical Oncology.

The effect of a bacterial vaccine on tumors and the immune response of ICR/Ha mice.

R. Axelrod, G. Schiffman, T. Shanahan, 1990, Journal of biological response modifiers.

Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC)

M. Carducci, D. Petrylak, M. Doukas, 2004 .